Latest news with #LanternPharmaInc
Yahoo
7 days ago
- Business
- Yahoo
Lantern Pharma Inc. (LTRN)'s LP-184 Shows 345% Survival Gain in Rare Pediatric Brain Tumor Models
Lantern Pharma Inc. (NASDAQ:LTRN)'s investigational drug LP-184 has achieved a major milestone in the fight against pediatric brain cancer, following independent validation by Johns Hopkins University researchers. New preclinical data presented at the Society for Neuro-Oncology's Pediatric Conference showed LP-184 extended survival dramatically in mouse models of atypical teratoid rhabdoid tumors (ATRT), a rare and aggressive childhood brain cancer. In one model, median survival soared from 20 to 89 days, which is a 345% improvement, while another saw an increase from 68 to 98 days. The studies also confirmed strong anti-tumor activity across multiple ATRT subtypes and favorable blood-brain barrier penetration, with no apparent toxicity observed in treated animals. A healthcare provider holding an MRI scan of a patient with a traumatic brain injury. These results strengthen the scientific foundation for Lantern Pharma Inc. (NASDAQ:LTRN)'s FDA Rare Pediatric Disease Designation for LP-184 in ATRT and pave the way for a planned pediatric clinical trial, expected to launch in late 2025 or early 2026. LP-184, a next-generation acylfulvene drug, targets tumors with epigenetic dysregulation, such as those with SMARCB1 gene loss, a hallmark of ATRT. With current treatments offering poor outcomes and high toxicity, Lantern Pharma Inc. (NASDAQ:LTRN)'s LP-184's single-agent efficacy could mark a breakthrough for children facing this devastating diagnosis. LTRN closed over 9% higher on May 29. While we acknowledge the potential of LTRN to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than LTRN and that has 100x upside potential, check out our report about this READ NEXT: and Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
05-05-2025
- Business
- Business Wire
Lantern Advances Drug Candidate LP-184 with IND Clearance for Phase 1b/2 Clinical Trial in Triple Negative Breast Cancer (TNBC)
DALLAS--(BUSINESS WIRE)--Lantern Pharma Inc. (Nasdaq: LTRN), an artificial intelligence company developing targeted and transformative cancer therapies using its proprietary AI platform, RADR ®, today announced that it has received clearance of its Investigational New Drug Application (IND) from the U.S. Food and Drug Administration (FDA) for a Phase 1b/2 clinical trial for LP-184 in Triple Negative Breast Cancer. This achievement builds on the previous regulatory momentum including Orphan Drug Designation in 2023 and Fast Track Designation in 2024 1. "This IND clearance for LP-184 in a Phase 1b/2 study represents a pivotal advancement in our mission to bring precisely targeted, AI-developed medicines to patients with aggressive cancers and limited treatment options," said Panna Sharma, CEO & President. Share Strategic Trial Design to Address Critical Treatment Gap in TNBC The innovative dual-approach in the clinical trial is designed to evaluate LP-184 in recurrent, advanced-stage TNBC patients through: Monotherapy Arm: An open-label study involving approximately 30 patients with advanced-stage TNBC, focusing on dose optimization to evaluate, enhance and optimize safety and potential efficacy for TNBC patients. Combination Therapy: Evaluation of LP-184 in combination with olaparib in second-line settings for patients with advanced-stage TNBC harboring BRCA1 or BRCA2 alterations, with primary endpoints including safety and efficacy parameters that could potentially support a pathway to regulatory approval. This strategic approach focuses on addressing a significant unmet medical need, with average survival for newly diagnosed metastatic TNBC estimated at 10 to 18 months, representing an annual market opportunity exceeding $4 billion USD. LP-184 Background in TNBC & Mechanistic Rationale LP-184 is a synthetically lethal small molecule that induces DNA double strand breaks upon bioactivation by the enzyme prostaglandin reductase 1 (PTGR1) in cancer cells. Preclinical studies and artificial intelligence-driven in silico modeling suggest that cancers with DDR gene alterations may preferentially respond to LP-184. 2 Preclinical findings also suggest that LP-184 is particularly well positioned for TNBC with striking data from in vivo models including complete regression seen in several PARP resistant as well as PARP sensitive PDXs (see Figure 1). Nearly 70% of TNBCs are noted to harbor deficiency in homologous recombination pathways, making them likely to be particularly sensitive tumors for targeting with drug-candidate LP-184. In addition, it is estimated that up to 46% percent of women with TNBC will develop brain metastasis 3, and LP-184 has shown blood brain barrier (BBB) penetration, with evidence of activity in preclinical brain metastasis models. LP-184 Phase 1b/2 TNBC Trial Overview - Monotherapy The monotherapy phase 1b/2 trial is designed to evaluate LP-184 in patients with advanced-stage TNBC. The study is designed to focus on dose optimization to evaluate and enhance both safety and potential efficacy ultimately aiding in the potential determination of the best clinical position for LP-184 in advanced-stage TNBC patients. The design of the dose optimization phase, provides for evaluation of the safety, efficacy and pharmacokinetics of LP-184 using 2 dose levels in an open-label monotherapy study involving around 30 patients to be dosed with LP-184. LP-184 Phase 1b/2 TNBC Trial Overview - Combination Therapy with PARP inhibitor LP-184 has also been shown in preclinical studies to be highly potent in combination with the PARP inhibitor, olaparib, including in tumors that are resistant to PARP inhibitors. In preclinical studies, treatment of a HBCx-28 TNBC PDX model, with BRCA-1 LOH and an HRD score of 63 that was resistant to the PARP inhibitor, showed evidence of re-sensitization in combination with LP-184 (See Figure 2). These data, which were initially presented at the San Antonio Breast Cancer Symposium, support the clinical evaluation of LP-184 in combination with PARPi in an earlier line of treatment. Treating patients in an earlier clinical setting has the potential to reach more patients and potentially generate a more durable and deeper earlier control of the disease. The design of the combination phase 1b/2 trial provides for LP-184 to be evaluated in a second-line setting in patients with advanced-stage TNBC whose primary tumor harbors alterations in BRCA1 or BRCA2. The primary end points of the study are expected to include safety and efficacy, with the aim of supporting a potential pathway to a regulatory approval process. Multi-Region Clinical Strategy with Focus on High-Incidence Countries The trials are planned to be conducted at select centers in the United States as well as academic cancer centers and institutions in India and Nigeria, where TNBC incidence rates are particularly high—comprising nearly 40% of initial breast cancer diagnoses. This strategic site selection is focused on leveraging established collaborative research networks that have a track record of successful collaborative cancer studies with US and European pharma companies. Lantern's planned objective will be to ensure proper local experience and support for this clinical trial while addressing regions with significant disease burden and high clinical demand. "This IND clearance for LP-184 in a Phase 1b/2 study represents a pivotal advancement in our mission to bring precisely targeted, AI-developed medicines to patients with aggressive cancers and limited treatment options," said Panna Sharma, CEO and President of Lantern Pharma. "The strategic design of our clinical program reflects both the compelling mechanistic rationale and the encouraging data supporting LP-184's potential in TNBC." Expanding Therapeutic Potential Across Multiple Indications Beyond TNBC, LP-184 shows promise for the potential treatment of other cancers harboring DNA damage repair mutations, including lung, bladder, pancreatic, and ovarian cancers. Additional clinical trials in these targeted indications are in planning stages, with several being considered as Investigator Initiated Trials. LP-184 has received multiple Orphan Drug, Fast Track, and Rare Pediatric Disease Designations from the FDA across various solid tumor indications. The global TNBC market is estimated at $3-5 billion USD annually, with over 300,000 new cases diagnosed worldwide each year. While homologous recombination deficient TNBCs are often initially treated with PARP inhibitors, resistance inevitably develops, underscoring the critical need for novel therapeutic approaches. About Lantern Pharma Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR ®, leverages over 100 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of drug-candidates that span multiple cancer indications, including both solid tumors and blood cancers and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2–3 years and at approximately $1.0 – $2.5 million per program. Our lead development programs include a Phase 2 clinical program and multiple Phase 1 clinical trials. We have also established a wholly-owned subsidiary, Starlight Therapeutics, to focus exclusively on the clinical execution of our promising therapies for CNS and brain cancers, many of which have no effective treatment options. Our AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 billion USD and have the potential to provide life-changing therapies to hundreds of thousands of cancer patients across the world. Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR ® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR ® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "model," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that we may not be able to secure sufficient future funding when needed and as required to advance and support our existing and planned clinical trials and operations, (ii) the risk that observations in preclinical studies and early or preliminary observations in clinical studies do not ensure that later observations, studies and development will be consistent or successful, (iii) the risk that our research and the research of our collaborators may not be successful, (iv) the risk that we may not be successful in licensing potential candidates or in completing potential partnerships and collaborations, (v) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (vi) the risk that no drug product based on our proprietary RADR ® AI platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (vii) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission on March 27, 2025. You may access our Annual Report on Form 10-K for the year ended December 31, 2024 under the investor SEC filings tab of our website at or on the SEC's website at Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations.
Yahoo
02-04-2025
- Business
- Yahoo
Lantern Pharma Inc (LTRN) Q4 2024 Earnings Call Highlights: Navigating Growth and Challenges
General and Administrative Expenses (Q4 2024): Approximately $1.6 million, up from $1.3 million in Q4 2023. R&D Expenses (Q4 2024): Approximately $4.3 million, up from $3.6 million in Q4 2023. Net Loss (Q4 2024): Approximately $5.9 million or $0.54 per share, compared to $4.2 million or $0.39 per share in Q4 2023. R&D Expenses (Full Year 2024): Approximately $16.1 million, up from $11.9 million in 2023. General and Administrative Expenses (Full Year 2024): Approximately $6.1 million, up slightly from $6 million in 2023. Net Loss (Full Year 2024): Approximately $20.8 million or $1.93 per share, compared to $16 million or $1.47 per share in 2023. Cash Position (End of 2024): Approximately $24 million in cash equivalents and marketable securities. Shares Outstanding (End of 2024): 10,784,725 shares of common stock, with a total fully diluted shares outstanding of approximately 12.1 million shares. Warning! GuruFocus has detected 1 Warning Sign with LTRN. Release Date: March 27, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Lantern Pharma Inc (NASDAQ:LTRN) has made significant progress in its clinical pipeline and AI platform, with three AI-driven drugs advancing into clinical trials at a rapid pace and lower cost. The company's LP 300 drug has shown promising preliminary results in the harmonic trial, achieving an 86% clinical benefit rate and a 43% objective response rate in never smoker non-small cell lung cancer patients. Lantern Pharma Inc (NASDAQ:LTRN) received two FDA fast track designations for LP 184 in glioblastoma and triple negative breast cancer, indicating regulatory validation and potential for expedited clinical development. The company's AI platform, RADar, has expanded to over 100 billion oncology-specific data points, enhancing its ability to identify non-obvious relationships and potential combination strategies. Lantern Pharma Inc (NASDAQ:LTRN) has a strong cash position with $24 million in cash equivalents and marketable securities, providing a runway to fund operations for at least 12 months. Lantern Pharma Inc (NASDAQ:LTRN) reported a net loss of approximately $20.8 million for the full year 2024, an increase from the previous year's loss of $16 million. The company anticipates needing substantial additional funding in the near future to continue its operations and development programs. R&D expenses increased significantly, from $11.9 million in 2023 to $16.1 million in 2024, primarily due to research studies and clinical trial support. The enrollment in clinical trials has been slower than expected, with dose levels for LP 184 reaching higher than anticipated, extending the timeline for results. Lantern Pharma Inc (NASDAQ:LTRN) faces challenges in securing partnerships and collaborations, as potential deals often break down over financial and resource allocation issues. Q: How is the pace and quality of enrollment in Asia compared to the US? A: The pace of enrollment in Asia is about 2 to 4 times faster than in the US. The sites in Asia ramped up faster, and in the past few months, the output from Asia has matched that of the US, with a much quicker timeline from onboarding to first patient. This trend is expected to continue, potentially reaching 3 to 4 times faster enrollment this year due to the Asian sites. - Panna Sharma, CEO Q: What are the opportunities for ADCs that substitute the toxic payload with another immunotherapy? A: Substituting the toxic payload with another immunotherapy, such as an immunomodulating agent, is possible and is an area of interest. There is potential for innovation in designing multi-payload ADCs, which could include both immunomodulating and toxic payloads. However, testing these complex architectures, especially in non-human primates, remains a challenge. This area is well-suited for AI-driven precision biology and data collection. - Panna Sharma, CEO Q: Can you provide an update on the harmonic trial data expected later this year? A: We have enrolled a significant number of patients in Asia and the US, and we continue to see positive clinical benefit trends. We expect to have a mid to late Q2 readout, with a key update at 30 events, likely closer to the end of the year. This will help decide whether to proceed to a larger trial and potentially partner the asset. - Panna Sharma, CEO Q: What should we look for next in your ADC programs? A: We have exciting pre-clinical data, particularly in HER2 low and medium expressing cancers, showing higher potency than existing FDA-approved agents. We are also working on new payloads that are significantly more potent. Expect more pre-clinical data and announcements of partnerships using our ADC AI platform as an analytical tool. - Panna Sharma, CEO Q: Why was the LP 184 data delayed, and when can we expect results? A: The delay was due to higher dose levels being reached in the trial, which extended the timeline. We are now in cohort 11 or 12, with each cohort taking about a month. We have not seen significant adverse events and are beginning to see therapeutic levels of efficacy. Results are expected once these higher dose levels are fully evaluated. - Panna Sharma, CEO For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Sign in to access your portfolio
Yahoo
20-03-2025
- Business
- Yahoo
Lantern Pharma to Report Fourth Quarter and Fiscal Year 2024 Operating & Financial Results on March 27th, 2025 at 4:30 p.m. ET
Webcast to be held Thursday, March 27th, 4:30 p.m. ET, register for the webcast here, or at the link provided below. DALLAS, March 20, 2025--(BUSINESS WIRE)--Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence ("AI") company developing targeted and transformative cancer therapies using its proprietary RADR® AI and machine learning ("ML") platform with multiple clinical stage drug programs, today announced that it will host its fourth quarter and fiscal year 2024 operating and financial results webcast on Thursday, March 27, 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time. Management intends to discuss the operating and financial results for the fourth quarter and fiscal year ended December 31, 2024 and provide guidance on upcoming milestones, clinical trials and developments of the AI platform, RADR®. Panna Sharma, President and Chief Executive Officer of Lantern Pharma, will lead the call and will be joined by other members of the management team. To register for the webinar, please sign up at the Zoom webcast link provided in the link: Lantern Pharma Q4, 2024 earnings Zoom webcast registration link. A replay of the earnings call webcast will be available after the call on the investor relations section of the Company's website: About Lantern Pharma Lantern Pharma (NASDAQ: LTRN) is an AI company transforming the cost, pace, and timeline of oncology drug discovery and development. Our proprietary AI and machine learning (ML) platform, RADR®, leverages over 100 billion oncology-focused data points and a library of 200+ advanced ML algorithms to help solve billion-dollar, real-world problems in oncology drug development. By harnessing the power of AI and with input from world-class scientific advisors and collaborators, we have accelerated the development of our growing pipeline of therapies that span multiple cancer indications, including both solid tumors and blood cancers and an antibody-drug conjugate (ADC) program. On average, our newly developed drug programs have been advanced from initial AI insights to first-in-human clinical trials in 2-3 years and at approximately $1.0 - 2.5 million per program. Our lead development programs include a Phase 2 clinical program and multiple Phase 1 clinical trials. We have also established a wholly-owned subsidiary, Starlight Therapeutics, to focus exclusively on the clinical execution of our promising therapies for CNS and brain cancers, many of which have no effective treatment options. Our AI-driven pipeline of innovative product candidates is estimated to have a combined annual market potential of over $15 billion USD and have the potential to provide life-changing therapies to hundreds of thousands of cancer patients across the world. Additional information: Website: LinkedIn: X: @lanternpharma Forward-Looking Statements: This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, among other things, statements relating to: future events or our future financial performance; the potential advantages of our RADR® platform in identifying drug candidates and patient populations that are likely to respond to a drug candidate; our strategic plans to advance the development of our drug candidates and antibody drug conjugate (ADC) development program; estimates regarding the development timing for our drug candidates and ADC development program; expectations and estimates regarding clinical trial timing and patient enrollment; our research and development efforts of our internal drug discovery programs and the utilization of our RADR® platform to streamline the drug development process; our intention to leverage artificial intelligence, machine learning and genomic data to streamline and transform the pace, risk and cost of oncology drug discovery and development and to identify patient populations that would likely respond to a drug candidate; estimates regarding patient populations, potential markets and potential market sizes; sales estimates for our drug candidates and our plans to discover and develop drug candidates and to maximize their commercial potential by advancing such drug candidates ourselves or in collaboration with others. Any statements that are not statements of historical fact (including, without limitation, statements that use words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "model," "objective," "aim," "upcoming," "should," "will," "would," or the negative of these words or other similar expressions) should be considered forward-looking statements. There are a number of important factors that could cause our actual results to differ materially from those indicated by the forward-looking statements, such as (i) the risk that our research and the research of our collaborators may not be successful, (ii) the risk that observations in preclinical studies and early or preliminary observations in clinical studies do not ensure that later observations, studies and development will be consistent or successful, (iii) the risk that we may not be able to secure sufficient future funding when needed and as required to advance and support our existing and planned clinical trials and operations, (iv) the risk that we may not be successful in licensing potential candidates or in completing potential partnerships and collaborations, (v) the risk that none of our product candidates has received FDA marketing approval, and we may not be able to successfully initiate, conduct, or conclude clinical testing for or obtain marketing approval for our product candidates, (vi) the risk that no drug product based on our proprietary RADR® AI platform has received FDA marketing approval or otherwise been incorporated into a commercial product, and (vii) those other factors set forth in the Risk Factors section in our Annual Report on Form 10-K for the year ended December 31, 2023, filed with the Securities and Exchange Commission on March 18, 2024. You may access our Annual Report on Form 10-K for the year ended December 31, 2023 under the investor SEC filings tab of our website at or on the SEC's website at Given these risks and uncertainties, we can give no assurances that our forward-looking statements will prove to be accurate, or that any other results or events projected or contemplated by our forward-looking statements will in fact occur, and we caution investors not to place undue reliance on these statements. All forward-looking statements in this press release represent our judgment as of the date hereof, and, except as otherwise required by law, we disclaim any obligation to update any forward-looking statements to conform the statement to actual results or changes in our expectations. View source version on Contacts Investor Relations Contact: Investor Relations at Lantern Pharmair@ Sign in to access your portfolio
Yahoo
28-01-2025
- Business
- Yahoo
Lantern Pharma Inc. (LTRN) Enhances RADR® AI Platform to Accelerate Development of Antibody-Drug Conjugates (ADCs) for Targeted Cancer Therapies
We recently compiled a list of the . In this article, we are going to take a look at where Lantern Pharma Inc. (NASDAQ:LTRN) stands against the other AI stocks. The artificial intelligence community is raving over a new reasoning model that has surprised even Silicon Valley. Developed by Chinese start-up DeepSeek, the r1 claims to match and even exceed OpenAI's o1 by multiple benchmarks, and that too, at a fraction of the cost. A Chinese hedge-fund manager, Liang Wenfeng, has led the development of r1. Wenfeng has become the leading figure in the country's AI initiative. 'Deepseek R1 is one of the most amazing and impressive breakthroughs I've ever seen'. While some specialists are saying that DeepSeek's technology is a bit behind OpenAI and Google, it is still an achievement considering it has used fewer and less advanced chips. The country has also had to deal with US restrictions along the way, implying how DeepSeek either found a way around the rules or the controls weren't stringent enough in the first place. READ NOW: 10 AI Stocks Making Waves on Wall Street and Also developed by DeepSeek is its AI assistant, an artificial intelligence application that was released on January 10. The AI assistant is powered by the DeepSeek-V3 model and boasts over 600 billion parameters. It is designed to assist users by offering them seamless interactions, answering user questions, and enhancing daily tasks. In the latest news, Reuters reports how the Chinese startup DeepSeek's AI Assistant has overtaken rival ChatGPT to become the top-rated free application available on Apple's App Store in the United States. According to its creators, the AI assistant "tops the leaderboard among open-source models and rivals the most advanced closed-source models globally'. Both the r1 and AI assistant by DeepSeek are proof that China is getting closer to the US in the race toward supremacy in AI. While several Chinese tech companies have released tech companies over the past, DeepSeek has been particularly praised by the US tech industry for its innovation and achievements. At the same time, there is skepticism regarding how these cheaper alternatives may question the pricing power of US tech giants and if their spending needs need to be re-evaluated. 'While it remains to be seen if DeepSeek will prove to be a viable, cheaper alternative in the long term, initial worries are centered on whether US tech giants' pricing power is being threatened and if their massive AI spending needs re-evaluation'. For this article, we selected AI stocks by going through news articles, stock analysis, and press releases. These stocks are also popular among hedge funds. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 275% since May 2014, beating its benchmark by 150 percentage points (). A researcher standing in a modern laboratory, surrounded by scientific Pharma Inc. (NASDAQ:LTRN) uses artificial intelligence, machine learning, and genomic data through its RADR platform to advance precision oncology. On January 27, the company announced improvements to its RADR® AI platform aimed at accelerating and optimizing the development of antibody-drug conjugates (ADCs). ADC is a process of creating Antibody-Drug Conjugates, a type of targeted cancer therapy for the treatment of the disease. The company's AI-driven approach has already identified 82 promising ADC targets and 290 target-indication combinations, with some already validated for use. The AI-powered ADC module could speed up drug development by up to 50% and lower costs by 60%. It would also reduce both the time and cost of ADC development while also increasing the probability of clinical success. The company has been actively advancing multiple ADC candidates through preclinical development and has also engaged in a collaboration with the prestigious MAGICBULLET::Reloaded Initiative at the University of Bielefeld in Germany. "The implications of this research extend far beyond just expanding the repertoire of potential ADC targets. By leveraging our RADR® platform's advanced AI capabilities, we've created a systematic approach that could dramatically reduce both the time and cost of ADC development while increasing the probability of clinical success. Our platform is particularly well-suited for partnership opportunities with pharmaceutical companies looking to accelerate their ADC programs or expand their pipeline with novel targets'. Overall LTRN ranks 8th on our list of the top AI stocks that are dominating Wall Street. While we acknowledge the potential of LTRN as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter timeframe. If you are looking for an AI stock that is more promising than LTRN but that trades at less than 5 times its earnings, check out our report about the . READ NEXT: and Complete List of All AI Companies Under $2 Billion Market Cap. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio
